for people ages 18-80 (full criteria)
study started
completion around
Principal Investigator
by Siddharth Padia (ucla)



The purpose of this clinical research study is to examine whether embolization treatment of an elbow artery is a safe and effective way to treat elbow pain, specifically pain from tennis elbow. Embozene is a medical device made by Varian marketed in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery to block the flow of blood to a specific region. One of the causes of pain in the setting of tennis elbow is increased blood flow going to the specific area of pain. In this study, we will investigate an experimental procedure to decrease the blood flow (embolize) to the specific region of the elbow that is causing the pain. This will be done by infusing Embozene particles into the specific blood vessel supplying the area of pain in the elbow. This is an investigational study to evaluate the safety and efficacy of elbow artery embolization (EAE) for the treatment of symptomatic lateral epicondylitis (tennis elbow).

Official Title

Safety and Efficacy of Elbow Artery Embolization (EAE) for the Treatment of Lateral Epicondylitis


This is a single-center, prospective, single arm investigational study to evaluate the safety of elbow artery embolization (EAE) for treatment of symptomatic lateral epicondylitis. In addition, the improvement as part of efficacy will be reported. All patients will have either failed or be intolerant to conservative management. Patients will be considered enrolled in the study once they have provided informed consent and have been determined to meet all eligibility criteria. A total of 25 patients will be enrolled in the single treatment arm of the study and will be followed for 24 months.

The study will involve a screening period in which patient eligibility is determined. Once eligibility is confirmed, subjects will undergo EAE with Embozene microspheres (75 micron). Following treatment, subjects will return for follow-up visits at 1 week, 1 month (± 2 weeks), 3 months (± 2 weeks), 6 months (± 4 weeks), 12 months (± 4 weeks), and 24 months (± 4 weeks) post-procedure. At these visits, subjects will undergo a directed physical examination, report any new adverse events (AEs), and complete questionnaires. At 12 months of follow-up, subjects will also undergo elbow MRI and x-ray.


Lateral Epicondylitis, Unspecified Elbow, tennis elbow, embolization, embozene, Embozene particles, Elbow Artery Embolization (EAE)


You can join if…

Open to people ages 18-80

  • Age ≥ 18 years and less than 80 years
  • Diagnosis of lateral epicondylitis based on history and physical exam
  • Ability to provide informed consent
  • Life expectancy greater than 12 months
  • Moderate-severe lateral elbow pain as determined by visual analog scale > 4 (based on average severity during physical activity)
  • Resistant/failed conservative treatment (e.g. NSAIDS/physical therapy/steroid joint injection) for at least 6 months.

You CAN'T join if...

  • Mild elbow pain as determined by visual analog scale < 4
  • Chronic renal insufficiency (serum creatinine >2 mg/dL)
  • Allergy to iodinated contrast agents that is not responsive to steroid management
  • Active Infection or malignancy
  • Prior elbow surgery in the subject elbow
  • Uncorrectable bleeding diathesis


  • University of California, Los Angeles accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at University of California Health

  • Siddharth Padia (ucla)
    HS Clinical Professor, Radiological Sciences, Medicine. Authored (or co-authored) 80 research publications


accepting new patients
Start Date
Completion Date
Siddharth Padia, MD
Study Type
Expecting 25 study participants
Last Updated